These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28761687)

  • 41. Association between the -174 C/G polymorphism in the interleukin-6 (IL-6) gene and gastrointestinal involvement in patients with systemic sclerosis.
    Zekovic A; Vreca M; Spasovski V; Andjelkovic M; Pavlovic S; Damjanov N
    Clin Rheumatol; 2018 Sep; 37(9):2447-2454. PubMed ID: 29948346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.
    Khanna D; Hays RD; Park GS; Braun-Moscovici Y; Mayes MD; McNearney TA; Hsu V; Clements PJ; Furst DE
    Arthritis Rheum; 2007 Oct; 57(7):1280-6. PubMed ID: 17907224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility.
    Kawaguchi Y; Nakamura Y; Matsumoto I; Nishimagi E; Satoh T; Kuwana M; Sumida T; Hara M
    Ann Rheum Dis; 2009 May; 68(5):710-4. PubMed ID: 18762475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The microbiome and systemic sclerosis: A review of current evidence.
    Tan TC; Noviani M; Leung YY; Low AHL
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101687. PubMed ID: 33849778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Furst DE; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Hays RD
    J Rheumatol; 2011 Sep; 38(9):1920-4. PubMed ID: 21724699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease.
    Low AHL; Teng GG; Pettersson S; de Sessions PF; Ho EXP; Fan Q; Chu CW; Law AHN; Santosa A; Lim AYN; Wang YT; Haaland B; Thumboo J
    Semin Arthritis Rheum; 2019 Dec; 49(3):411-419. PubMed ID: 31208714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunoglobulins in systemic sclerosis management. A large multicenter experience.
    Tandaipan J; Guillén-Del-Castillo A; Simeón-Aznar CP; Carreira PE; De la Puente C; Narváez J; Lluch J; Rubio-Rivas M; Alegre-Sancho JJ; Bonilla G; Moriano C; Casafont-Sole I; García-Vicuña R; Ortiz-Santamaría V; Riera E; Atienza-Mateo B; Blanco R; Galisteo C; Gonzalez-Martin JJ; Pego-Reigosa JM; Pros A; Heredia S; Castellví I
    Autoimmun Rev; 2023 Nov; 22(11):103441. PubMed ID: 37708984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization.
    Luebker S; Frech TM; Assassi S; Skaug B; Gordon JK; Lakin K; Bernstein EJ; Luo Y; Steen VD; Shah AA; Hummers LK; Richardson C; Moore DF; Khanna D; Castelino FV; Chung L; Kapoor P; Hant FN; Shanmugam VK; VanBuren JM; Alvey J; Harding M; Shah A; Makol A; Lebiedz-Odrobina D; Thomas JK; Volkmann ER; Molitor JA; Sandorfi N
    Rheumatology (Oxford); 2023 Oct; 62(10):3433-3438. PubMed ID: 37079727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
    Nagaraja V; Hays RD; Khanna PP; Spiegel BM; Chang L; Melmed GY; Bolus R; Khanna D
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1725-30. PubMed ID: 24692332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nutritional status and gastrointestinal symptoms in systemic sclerosis patients.
    Murtaugh MA; Frech TM
    Clin Nutr; 2013 Feb; 32(1):130-5. PubMed ID: 22770637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gut microbiome in systemic sclerosis: a potential therapeutic target.
    Polkowska-Pruszyńska B; Gerkowicz A; Rawicz-Pruszyński K; Krasowska D
    Postepy Dermatol Alergol; 2022 Feb; 39(1):101-109. PubMed ID: 35369617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis.
    Maclean RH; Ahmed F; Ong VH; Murray CD; Denton CP
    J Rheumatol; 2023 Jul; 50(7):907-915. PubMed ID: 36792109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physical frailty in patients with systemic sclerosis.
    Hax V; Tessari J; Pena E; Santo RCDE; Dos Santos LP; Gasparin AA; Bredemeier M; Fighera TM; Spritzer PM; Xavier RM; Chakr RMDS
    Semin Arthritis Rheum; 2022 Oct; 56():152077. PubMed ID: 35952534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.
    Suliman Y; Kafaja S; Oh SJ; Alemam M; Bagnato G; Abignano G; Singh RR; Barlow G; Liu X; Valera I; Morales W; Rezaie A; Pimentel M; Del Galdo F; Furst DE
    Clin Rheumatol; 2021 Jun; 40(6):2277-2284. PubMed ID: 33231773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.
    Luebker S; Frech TM; Assassi S; Gordon JK; Bernstein EJ; Steen VD; Shah AA; Hummers LK; Richardson C; Khanna D; Castelino FV; Chung L; Hant FN; Shanmugam VK; VanBuren JM; Alvey J; Harding M; Sandorfi N
    Clin Exp Rheumatol; 2023 Aug; 41(8):1632-1638. PubMed ID: 37497718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality.
    Horsley-Silva JL; Umar SB; Vela MF; Griffing WL; Parish JM; DiBaise JK; Crowell MD
    Dis Esophagus; 2019 May; 32(5):. PubMed ID: 30715227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of faecal microbiota transplantation on the small intestinal mucosa in systemic sclerosis.
    Strahm N; Didriksen H; Fretheim H; Molberg Ø; Midtvedt Ø; Farstad IN; Midtvedt T; Lundin KEA; Aabakken L; Błyszczuk P; Distler O; Kania G; Hoffmann-Vold AM
    Rheumatology (Oxford); 2023 Aug; 62(8):2918-2929. PubMed ID: 36688692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The assessment of malnutrition and severity of gastrointestinal disease by using symptom-based questionnaires in systemic sclerosis: is it related to severe organ involvement or capillary rarefaction at microcirculation?
    Yalcinkaya Y; Erturk Z; Unal AU; Kaymaz Tahra S; Pehlivan O; Atagunduz P; Direskeneli H; Inanç N
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):127-131. PubMed ID: 32141434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status.
    Natalello G; Bosello SL; Paroni Sterbini F; Posteraro B; De Lorenzis E; Canestrari GB; Gigante L; Verardi L; Ferraccioli G; Sanguinetti M; Gremese E
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):73-84. PubMed ID: 32865168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.